Inotek Pharmaceuticals Corp (RCKT):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Inotek Pharmaceuticals Corp (RCKT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7975
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:33
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Inotek Pharmaceuticals Corp (IPC) is a clinical-stage biopharmaceutical company that focus on the discovery and development of novel therapeutics for the treatment of glaucoma and serious diseases of the eye. The company’s trabodenoson is a selective adenosine mimetic that stimulates a specific adenosine subreceptor. Its Trabodenoson technology is a potential new therapy for ocular hypertension (OHT) and primary open-angle glaucoma (POAG) that restores natural state in the eye by mimicking the action of adenosine. The company also sponsors Phase 1, Phase 2 and Phase 3 clinical trials for trabodenoson monotherapy, which have concluded, and Phase 2 clinical trial for trabodenoson plus latanoprost in a fixed-dose combination. IPC is headquartered in Lexington, Massachusetts, the US.

Inotek Pharmaceuticals Corp (RCKT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Inotek Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Inotek Pharmaceuticals Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Inotek Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Inotek Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Inotek Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Inotek Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Inotek Pharma Raises US$21 Million In Venture Financing 11
Partnerships 13
Rocket Pharmaceuticals and Stanford University School of Medicine Enter into Partnership 13
Merger 14
Inotek Pharma Completes Merger with Rocket Pharma 14
Equity Offering 16
Rocket Pharma Plans to Raise up to USD300 Million in Public Offering of Securities 16
Rocket Pharma Prices USD72.8 Million in Public Offering of Shares 17
Inotek Pharma Raises USD4.4 Million in Public Offering of Shares 18
Inotek Pharma Raises USD79.2 Million in Public Offering of Shares 19
Inotek Pharma Raises USD40 Million in IPO 21
Debt Offering 23
Inotek Pharma Raises USD50 Million in Public Offering of 5.75% Notes Due 2021 23
Inotek Pharma Raises USD20 Million in Public Offering of 5% Notes Due 2020 25
Inotek Pharmaceuticals Corp – Key Competitors 27
Inotek Pharmaceuticals Corp – Key Employees 28
Inotek Pharmaceuticals Corp – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Aug 03, 2017: Inotek Pharmaceuticals Reports Second Quarter 2017 Financial Results and Operational Highlights 30
May 10, 2017: Inotek Pharmaceuticals Reports First Quarter 2017 Financial Results and Operational Highlights 31
Mar 16, 2017: Inotek Pharmaceuticals Reports Fiscal Year 2016 Financial Results and Operational Highlights 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33

List of Tables
Inotek Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Inotek Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Inotek Pharmaceuticals Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Inotek Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Inotek Pharmaceuticals Corp, Deals By Therapy Area, 2012 to YTD 2018 8
Inotek Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Inotek Pharma Raises US$21 Million In Venture Financing 11
Rocket Pharmaceuticals and Stanford University School of Medicine Enter into Partnership 13
Inotek Pharma Completes Merger with Rocket Pharma 14
Rocket Pharma Plans to Raise up to USD300 Million in Public Offering of Securities 16
Rocket Pharma Prices USD72.8 Million in Public Offering of Shares 17
Inotek Pharma Raises USD4.4 Million in Public Offering of Shares 18
Inotek Pharma Raises USD79.2 Million in Public Offering of Shares 19
Inotek Pharma Raises USD40 Million in IPO 21
Inotek Pharma Raises USD50 Million in Public Offering of 5.75% Notes Due 2021 23
Inotek Pharma Raises USD20 Million in Public Offering of 5% Notes Due 2020 25
Inotek Pharmaceuticals Corp, Key Competitors 27
Inotek Pharmaceuticals Corp, Key Employees 28
Inotek Pharmaceuticals Corp, Subsidiaries 29

List of Figures
Inotek Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Inotek Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Inotek Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Inotek Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Inotek Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Inotek Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Inotek Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Inotek Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Inotek Pharmaceuticals Corp (RCKT):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • LCH.Clearnet Group Limited:企業の戦略・SWOT・財務情報
    LCH.Clearnet Group Limited - Strategy, SWOT and Corporate Finance Report Summary LCH.Clearnet Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Nissin Electric Co Ltd (6641):企業の財務・戦略的SWOT分析
    Nissin Electric Co Ltd (6641) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Promaxo Inc:医療機器:M&Aディール及び事業提携情報
    Summary Promaxo Inc (Promaxo) is a medical device company with focus on the development of portable MRI and other technology. The company develops and commercializes office-based, portable magnetic resonance imaging (MRI) devices that possess cellular spatial resolution, besides targeted biopsy and …
  • Vectura Group Plc (VEC):医療機器:M&Aディール及び事業提携情報
    Summary Vectura Group Plc (Vectura) is a formulation and device business for inhaled airways products providing an integrated inhaled drug delivery platform. It develops inhalation products, to help patients suffering from airways diseases such as asthma, chronic obstructive pulmonary disease (COPD) …
  • National Rural Utilities Cooperative Finance Corporation:企業の戦略・SWOT・財務情報
    National Rural Utilities Cooperative Finance Corporation - Strategy, SWOT and Corporate Finance Report Summary National Rural Utilities Cooperative Finance Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the comp …
  • Devon Energy Corporation:企業の戦略・SWOT・財務分析
    Devon Energy Corporation - Strategy, SWOT and Corporate Finance Report Summary Devon Energy Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Oncolix Inc-製薬・医療分野:企業M&A・提携分析
    Summary Oncolix Inc (Oncolix) is a clinical stage biopharmaceutical company. It is developing a targeted therapeutic protein, Prolanta for the treatment of ovarian, breast and other cancers. Prolanta is a recombinant analogue to the human prolactin and acts as an antagonist to the prolactin receptor …
  • SNC-Lavalin Group Inc.:企業の戦略・SWOT・財務情報
    SNC-Lavalin Group Inc. - Strategy, SWOT and Corporate Finance Report Summary SNC-Lavalin Group Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • HemaCare Corp (HEMA):企業の財務・戦略的SWOT分析
    Summary HemaCare Corp (HemaCare) is a provider of biological blood products and services. The company offers primary blood cells and tissues derived from normal and mobilized peripheral blood, cord blood, and bone marrow. It spans its expertise in isolations, custom cell collections and testing of p …
  • Voltamp Energy SAOG (VOES):企業の財務・戦略的SWOT分析
    Voltamp Energy SAOG (VOES) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Martin Resource Management Corp:石油・ガス:M&Aディール及び事業提携情報
    Summary Martin Resource Management Corp (MRMC) is an oil and gas service provider that markets and distributes fuel oil, asphalt, sulfuric acid, diesel fuel and naphthenic lubricants. The company provides transportation, marketing, terminalling and logistics management services for hydrocarbon produ …
  • ATCC:製薬・医療:M&Aディール及び事業提携情報
    Summary ATCC is a nonprofit bioresource center and research organization that provides biological products, technical services and educational programs. The organization acquires, preserves, develops, authenticates, produces, and distributes standard reference microorganisms, cell lines and other ma …
  • Quickstep Holdings Limited:企業の戦略・SWOT・財務情報
    Quickstep Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Quickstep Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Genor BioPharma Co Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Genor BioPharma Co Ltd (Genor) a subsidiary of Walvax Biotechnology Co Ltd is a bio-pharmaceutical company which develops and commercializes therapeutic monoclonal antibodies (mAbs), Fc-fusion proteins and recombinant therapeutic proteins. Its service offerings include process and assay deve …
  • DH Private Equity Partners:企業の戦略・SWOT・財務情報
    DH Private Equity Partners - Strategy, SWOT and Corporate Finance Report Summary DH Private Equity Partners - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Franchise Services of North America Inc:戦略・SWOT・企業財務分析
    Franchise Services of North America Inc - Strategy, SWOT and Corporate Finance Report Summary Franchise Services of North America Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Sensus Healthcare Inc (SRTS):企業の財務・戦略的SWOT分析
    Sensus Healthcare Inc (SRTS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Petronas Dagangan Bhd (PETDAG):石油・ガス:M&Aディール及び事業提携情報
    Summary Petronas Dagangan Bhd (Petronas Dagangan), a subsidiary of Petroliam Nasional Berhad, is an oil and gas company that retails and markets downstream oil and gas products. The company operates through its business segments such as retail, commercial, liquefied petroleum gas and lubricants. It …
  • Shopper’s Stop Ltd.:企業の戦略・SWOT・財務情報
    Shopper's Stop Ltd. - Strategy, SWOT and Corporate Finance Report Summary Shopper's Stop Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Fortitech Inc.:戦略・SWOT・企業財務分析
    Fortitech Inc. - Strategy, SWOT and Corporate Finance Report Summary Fortitech Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆